Form 4: Regeneron Director Arthur Ryan Acquires Equity

Regeneron Pharmaceuticals Director Arthur F. Ryan acquired 155 restricted stock units and 1,962 non-qualified stock options on January 2, 2026.

Summary

• Arthur F. Ryan, a Director of Regeneron Pharmaceuticals, Inc. (REGN), acquired 155 shares of common stock through time-based vesting restricted stock units (RSUs) on January 2, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• Following this transaction, Arthur F. Ryan beneficially owns 17,903 shares of common stock directly.
• Additionally, Mr. Ryan acquired 1,962 non-qualified stock options on January 2, 2026, with an exercise price of $772.76 per share.
• These stock options have an expiration date of January 2, 2036.
• The options will vest partially on the date of the Issuer's first annual meeting of shareholders following the grant date, with the remainder vesting on the first anniversary of the grant date.
• Following this transaction, Mr. Ryan beneficially owns 1,962 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The acquisition of equity by a director, even as part of compensation, is generally viewed positively as it aligns the director's interests with shareholders and can signal confidence in the company's long-term prospects.

Positives

• A Director acquiring additional equity (even through grants) can signal confidence in the company's future performance.
• The grant of restricted stock units and stock options aligns the director's interests with those of shareholders, promoting long-term value creation.

Future Outlook

The acquired restricted stock units and stock options are subject to future vesting schedules, with options becoming exercisable partially on the date of the Issuer's first annual meeting following the grant date and the remainder on the first anniversary of the grant date, indicating future equity ownership and potential exercise events.

Industry Context

This filing is a standard disclosure of an insider equity transaction, common across all publicly traded companies, reflecting compensation practices for directors. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The acquisition of 155 restricted stock units and 1,962 non-qualified stock options by Director Arthur F. Ryan represents a transaction between the company and a related party (an insider).

Stakeholder Impact

• Shareholders: The equity grants align the director's incentives with shareholder value creation, potentially fostering long-term growth.
• Employees: Standard compensation practices for directors can influence overall compensation philosophy within the company.

Next Steps

• Vesting of the 155 restricted stock units into common stock.
• Vesting of the 1,962 non-qualified stock options, with a portion becoming exercisable on the date of the Issuer's first annual meeting following the grant date and the remainder on the first anniversary of the grant date.

Key Dates

Keywords

Regeneron, REGN, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Grant, Director Compensation